We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ENOXAPO (Apotex Pty Ltd)
Product name
ENOXAPO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
142 working days (255)
Active ingredients
enoxaparin sodium
Registration type
NCE/NBE
Indication
ENOXAPO (solution for injection) is indicated for the prevention of thromboembolic disorders of venous origin in patients undergoing orthopaedic and general surgery.
ENOXAPO is indicated for the prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness.
ENOXAPO is indicated for the prevention of thrombosis in extra-corporeal circulation during haemodialysis.
ENOXAPO is indicated for the treatment of established deep vein thrombosis.
ENOXAPO is indicated for the treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.
ENOXAPO is indicated for the treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI).